Decoding 6 Analyst Evaluations For Hims & Hers Health
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on Hims & Hers Health (NYSE:HIMS), with recent evaluations showing a mix of bullish and indifferent ratings. The average 12-month price target has increased to $22.17, indicating a positive outlook. The company has shown strong financial performance with significant revenue growth and efficient debt management.
October 21, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hims & Hers Health has received mixed analyst ratings, with a recent increase in the average price target to $22.17. The company shows strong financial performance, with a 51.82% revenue growth and a low debt-to-equity ratio, indicating a positive outlook.
The increase in the average price target and strong financial performance, including high revenue growth and low debt, suggest a positive short-term impact on HIMS stock. Analysts' mixed ratings are outweighed by the upward trend in price targets.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100